Summit Appoints Michael Donaldson as Chief Financial Officer
Oxford, UK, and Cambridge, MA, US, June 8, 2020 Summit Therapeutics plc (NASDAQ: SMMT) today announces that Mr. Michael Donaldson has been appointed as Chief Financial Officer, effective immediately.
- Oxford, UK, and Cambridge, MA, US, June 8, 2020 Summit Therapeutics plc (NASDAQ: SMMT) today announces that Mr. Michael Donaldson has been appointed as Chief Financial Officer, effective immediately.
- Mr. Donaldson brings to Summit over 20 years of finance experience, including the last nine years working in corporate finance.
- Summit has a clear focus and vision for bringing much-needed new antibiotic classes to market, beginning with ridinilazole, commented Mr. Donaldson.
- Mr. Donaldson joins Summit from Goldfinch Bio, Inc., where he led finance and accounting as Vice President, Finance, and Corporate Controller.